Shalini Sharp

2018 - Ultragenyx Pharmaceutical

In 2018, Shalini Sharp earned a total compensation of $2.1M as Chief Financial Officer and Executive Vice President at Ultragenyx Pharmaceutical, a 21% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$198,695
Option Awards$1,019,820
Salary$491,369
Stock Awards$339,010
Other$32,827
Total$2,081,721

Sharp received $1M in option awards, accounting for 49% of the total pay in 2018.

Sharp also received $198.7K in non-equity incentive plan, $491.4K in salary, $339K in stock awards and $32.8K in other compensation.

Rankings

In 2018, Shalini Sharp's compensation ranked 5,526th out of 14,244 executives tracked by ExecPay. In other words, Sharp earned more than 61.2% of executives.

ClassificationRankingPercentile
All
5,526
out of 14,244
61st
Division
Manufacturing
2,086
out of 5,765
64th
Major group
Chemicals And Allied Products
769
out of 2,128
64th
Industry group
Drugs
644
out of 1,817
65th
Industry
Pharmaceutical Preparations
497
out of 1,391
64th
Source: SEC filing on April 22, 2019.

Sharp's colleagues

We found six more compensation records of executives who worked with Shalini Sharp at Ultragenyx Pharmaceutical in 2018.

2018

Wladimir Hogenhuis

Ultragenyx Pharmaceutical

Chief Operating Officer

2018

Camille Bedrosian

Ultragenyx Pharmaceutical

Chief Medical Officer

2018

Emil Kakkis

Ultragenyx Pharmaceutical

Chief Executive Officer

2018

Karah Parschauer

Ultragenyx Pharmaceutical

General Counsel

2018

Thomas Kassberg

Ultragenyx Pharmaceutical

Chief Business Officer and Executive Vice President

2018

John Pinion

Ultragenyx Pharmaceutical

Chief Quality Officer and Executive Vice President, Translational Sciences

News

You may also like